Canaccord analyst Richard Close lowered the firm’s price target on AdaptHealth to $22 from $28 and keeps a Buy rating on the shares. The analyst said it was a disappointing quarter as the 4Q adjusted EBITDA result was well below preliminary commentary from early January and the early guide down for 2023 does not inspire confidence in the outlook.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AHCO:
